Episurf Medical’s Episealer® Patellofemoral System under substantive review at the US FDA

Episurf Medical (NASDAQ: EPIS B) today announces that the company’s 510(k) application to the US FDA for market clearance for the Episealer® Patellofemoral System now is progressing to the substantive review phase.

“This FDA notification is an important step in the process. We will continue our preparations for a US market launch while the application is undergoing the review” says Pål Ryfors, CEO Episurf Medical

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 21:00 CEST on 24 April 2022.

Tags: